Yale Cancer Center Partners in Fight to Help Eliminate HPV-related Cancers
Yale Cancer Center joins the Association of American Cancer Institutes (AACI) and its partner organizations to endorse a Call to Action for our nation to work together toward the elimination of human papillomavirus (HPV)-related cancers.
Researchers at Yale School of Public Health, GHLI Receive Funding from Gates Foundation for Global Projects
Researchers at the Yale School of Public Health and the Yale Global Health Leadership Initiative, in collaboration with international peers, have received Grand Challenges Explorations grants from the Bill & Melinda Gates Foundation for innovative research.
Vaccine Is a Cost-effective Solution for Countries Burdened by Typhoid
Introducing a typhoid conjugate vaccine (TCV) into routine child vaccine schedules and conducting a catch-up campaign to vaccinate all children up to age 15 is a cost-effective solution for many low- to middle-income countries severely burdened by typhoid, a new study led by researchers at the Yale School of Public Health finds.
Lyme Disease Is Spreading Fast. Why Isn’t There a Vaccine?
If Lyme has become so common, why isn’t there a vaccine for it? Well, here’s something you may not know: There used to be one, but it was taken off the market more than 15 years ago. And there’s only one new vaccine candidate in the pipeline.
A Zika Vaccine Could Virtually Eliminate Prenatal Infections
A Zika vaccine could have a substantial effect on mitigating and preventing future Zika virus outbreaks. Through a combination of direct protection and indirect reduction of transmissions, virtual elimination is achievable, even with imperfect vaccine efficacy and coverage, a new Yale School of Public Health study finds.
Opportunities to vaccinate young women against HPV missed at alarming rate
en aged 18-26 who were eligible to receive Human Papilloma Virus (HPV) vaccine have missed at least one opportunity to receive the vaccine during a visit to an obstetrics and gynecology clinic, Yale researchers report. This study also confirms previous research showing racial disparities in vaccination for HPV: Women who identify as black are 61% more likely have had a missed opportunity than women who identify as white. These findings are published in the American Journal of Obstetrics and Gynecology. HPV is a well-known cause of pre-cancerous cervical lesions, which, if untreated, could develop into cervical cancer. Immunization against HPV has been shown to be safe and effective in preventing these pre-cancerous lesions. The two-dose HPV vaccine is recommended for administration to It is recommended that girls ages 11-12 receive the two-dose HPV vaccine, and that those through age 26 receive the three-dose vaccination for “catch-up.”
$1.8 Million Granted to Yale School of Public Health to Study Effectiveness of HPV Vaccine
A $1.8 million National Institutes of Health grant will help researchers at the Yale School of Public Health shed light on the real-world effectiveness of the Human Papillomavirus (HPV) vaccine. Results of this study can ultimately help to maximize the vaccine’s impact on several types of cancer.
Precancerous Lesions Associated with HPV Dropping in Connecticut, YSPH Study Finds
The vaccine for the Human Papillomavirus (HPV) is proving to have significant population-level effects in Connecticut, with rates of precancerous lesions caused by HPV down drastically among young women, a new Yale School of Public Health study finds.